文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

药物稀释剂作为累积液体量和高氯血症的贡献者所隐藏的危害:一项前瞻性、开放标签、序贯阶段先导研究

Insidious Harm of Medication Diluents as a Contributor to Cumulative Volume and Hyperchloremia: A Prospective, Open-Label, Sequential Period Pilot Study.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在重症患者中,以生理盐水作为主要药物稀释剂与5%葡萄糖水相比,高氯血症发生率更高(17.9% vs 10.5%,p=0.037),校正后OR 0.50(95%CI 0.26-0.94,p=0.031)。

这项前瞻性、开放标签、序贯阶段先导研究在大型学术医疗中心的内科ICU进行,比较生理盐水与5%葡萄糖水作为主要药物稀释剂对重症患者高氯血症的影响。共纳入426例患者,盐水组216例,5%葡萄糖水组210例。药物稀释剂占观察期间总静脉液体量的63%。盐水组高氯血症发生率为17.9%,5%葡萄糖水组为10.5%(p=0.037),多变量分析显示统计学显著(OR 0.50,95%CI 0.26-0.94,p=0.031)。盐水组急性肾损伤发生率为34.2%,5%葡萄糖水组为24.5%(p=0.035),但校正基线协变量后无统计学显著性。

要点

  • 药物稀释剂占ICU患者总静脉液体量的63%,是累积液体量的重要来源。
  • 以生理盐水作为主要药物稀释剂时高氯血症发生率为17.9%,高于5%葡萄糖水组的10.5%(p=0.037)。
  • 多变量分析中,5%葡萄糖水组高氯血症风险低于盐水组(OR 0.50,95%CI 0.26-0.94,p=0.031)。
  • 盐水组急性肾损伤发生率为34.2%,5%葡萄糖水组为24.5%(p=0.035),但校正基线协变量后无统计学显著性。
  • 两组在钠代谢紊乱、胰岛素需求、血糖控制、ICU住院时间或ICU死亡率方面无其他显著差异。

适用人群与场景

  • 成人患者,收入大型学术医疗中心的内科ICU。
  • 排除:入住ICU时间少于48小时、年龄小于18岁、妊娠、被监禁或有脑损伤的患者。

研究设计与关键结果

  • 研究类型:前瞻性、开放标签、序贯阶段先导研究;单中心(大型学术医疗中心内科ICU)。
  • 样本量:共426例,盐水组216例,5%葡萄糖水组210例。
  • 干预:盐水作为主要药物稀释剂2个月,随后5%葡萄糖水作为主要药物稀释剂2个月。
  • 主要结果:药物稀释剂占观察期间总静脉液体量的63%;盐水组高氯血症发生率17.9% vs 5%葡萄糖水组10.5%(p=0.037);多变量分析OR 0.50(95%CI 0.26-0.94,p=0.031)。
  • 关键次要终点:盐水组急性肾损伤发生率34.2% vs 5%葡萄糖水组24.5%(p=0.035),校正基线协变量后无统计学显著性;钠代谢紊乱、胰岛素需求、血糖控制、ICU住院时间或ICU死亡率无其他显著差异。

证据类型、等级与局限

  • 证据类型:前瞻性、开放标签、序贯阶段先导研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,药物稀释剂对重症患者接受的总静脉液体量有实质性贡献,以生理盐水作为主要药物稀释剂相比5%葡萄糖水与高氯血症相关,而高氯血症可能是急性肾损伤的一个危险因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Although the potential dangers of hyperchloremia from resuscitation fluids continue to emerge, no study to date has considered the contribution of medication diluents to cumulative volume and hyperchloremia. This study compares saline versus dextrose 5% in water as the primary medication diluent and the occurrence of hyperchloremia in critically ill patients.

DESIGN: Prospective, open-label, sequential period pilot study.

SETTING: Medical ICU of a large academic medical center.

PATIENTS: Adult patients admitted to the medical ICU were eligible for inclusion. Patients who were admitted for less than 48 hours, less than 18 years old, pregnant, incarcerated, or who had brain injury were excluded.

INTERVENTIONS: Saline as the primary medication diluent for 2 months followed by dextrose 5% in water as the primary medication diluent for 2 months.

MEASUREMENTS AND MAIN RESULTS: A total of 426 patients were included, 216 in the saline group and 210 in the dextrose 5% in water group. Medication diluents accounted for 63% of the total IV volume over the observation period. In the saline group, 17.9% developed hyperchloremia compared with 10.5% in the dextrose 5% in water group (p = 0.037), which was statistically significant in multivariable analysis (odds ratio, 0.50; 95% CI, 0.26-0.94; p = 0.031). In the saline group, 34.2% developed acute kidney injury versus 24.5% in the dextrose 5% in water group (p = 0.035); however, this was not statistically significant when adjusting for baseline covariates. No other significant differences in dysnatremias, insulin requirements, glucose control, ICU length of stay, or ICU mortality were observed.

CONCLUSIONS: This study identified that medication diluents contribute substantially to the total IV volume received by critically ill patients. Saline as the primary medication diluent compared with dextrose 5% in water is associated with hyperchloremia, a possible risk factor for acute kidney injury.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Magee CA, Bastin MLT, Laine ME, et al. Insidious Harm of Medication Diluents as a Contributor to Cumulative Volume and Hyperchloremia: A Prospective, Open-Label, Sequential Period Pilot Study. Crit Care Med. 2018. PMID: 29727367. doi:10.1097/CCM.0000000000003191

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。